QNCX Key Statistics, Chart & Performance
The current stock price of QNCX is 3.45 USD. In the past month the price increased by 105.36%. In the past year, price increased by 68.29%.
QNCX Latest News, Press Relases and Analysis
QNCX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About QNCX
Company Profile
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. The company is headquartered in South San Francisco, California and currently employs 36 full-time employees. The company went IPO on 2019-05-09. The firm is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
Company Info
QUINCE THERAPEUTICS INC
601 Gateway Boulevard, Suite 1250
South San Francisco CALIFORNIA US
Employees: 36
Phone: 14159105717
QUINCE THERAPEUTICS INC / QNCX FAQ
Can you describe the business of QUINCE THERAPEUTICS INC?
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. The company is headquartered in South San Francisco, California and currently employs 36 full-time employees. The company went IPO on 2019-05-09. The firm is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
What is the stock price of QUINCE THERAPEUTICS INC today?
The current stock price of QNCX is 3.45 USD. The price increased by 29.21% in the last trading session.
Does QNCX stock pay dividends?
QNCX does not pay a dividend.
How is the ChartMill rating for QUINCE THERAPEUTICS INC?
QNCX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists QNCX stock?
QNCX stock is listed on the Nasdaq exchange.
What do analysts say about QUINCE THERAPEUTICS INC (QNCX) stock?
12 analysts have analysed QNCX and the average price target is 7.65 USD. This implies a price increase of 121.74% is expected in the next year compared to the current price of 3.45.
What is the GICS sector and industry of QNCX stock?
QUINCE THERAPEUTICS INC (QNCX) operates in the Health Care sector and the Biotechnology industry.
QNCX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to QNCX. When comparing the yearly performance of all stocks, QNCX is one of the better performing stocks in the market, outperforming 96.73% of all stocks.
QNCX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to QNCX. QNCX has a bad profitability rating. Also its financial health evaluation is rather negative.
QNCX Financial Highlights
Over the last trailing twelve months QNCX reported a non-GAAP Earnings per Share(EPS) of -1.1. The EPS decreased by -15.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.83% | ||
| ROE | -417.77% | ||
| Debt/Equity | 1.45 |
QNCX Forecast & Estimates
12 analysts have analysed QNCX and the average price target is 7.65 USD. This implies a price increase of 121.74% is expected in the next year compared to the current price of 3.45.